Pyxis Oncology Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
54
- Stock Symbol
-
PYXS
- Investments
-
2
- Share Price
-
$2.00
- (As of Monday Closing)
Pyxis Oncology General Information
Description
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Contact Information
Website
www.pyxisoncology.comCorporate Office
- 321 Harrison Avenue
- 11th Floor, Suite 1
- Boston, MA 02118
- United States
Corporate Office
- 321 Harrison Avenue
- 11th Floor, Suite 1
- Boston, MA 02118
- United States
Pyxis Oncology Timeline
Pyxis Oncology Stock Performance
As of 02-Dec-2024, Pyxis Oncology’s stock price is $2.00. Its current market cap is $119M with 59.5M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.00 | $2.01 | $1.59 - $6.85 | $119M | 59.5M | 1.06M | -$1.06 |
Pyxis Oncology Financials Summary
As of 30-Sep-2024, Pyxis Oncology has a trailing 12-month revenue of $16.1M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 83,230 | (31,568) | (135,455) | 420,291 |
| Revenue | 16,146 | 0 | 0 | 0 |
| EBITDA | (61,248) | (80,418) | (122,772) | (75,351) |
| Net Income | (57,357) | (73,790) | (120,717) | (75,975) |
| Total Assets | 195,311 | 173,726 | 211,379 | 280,021 |
| Total Debt | 20,540 | 21,331 | 18,921 | 165 |
Pyxis Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pyxis Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pyxis Oncology Comparisons
Industry
Financing
Details
Pyxis Oncology Competitors (55)
One of Pyxis Oncology’s 55 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Pyxis Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pyxis Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pyxis Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pyxis Oncology Investments & Acquisitions (2)
Pyxis Oncology’s most recent deal was a Merger/Acquisition with Apexigen for . The deal was made on 23-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Apexigen | 23-Aug-2023 | Merger/Acquisition | Drug Discovery | ||
| Kyma Therapeutics | 25-May-2021 | Joint Venture | Drug Discovery |
Pyxis Oncology ESG
Risk Overview
Risk Rating
Updated September, 01, 2022
34.12 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Pharmaceuticals
Subindustry
of 455
Rank
Percentile
Pyxis Oncology FAQs
-
When was Pyxis Oncology founded?
Pyxis Oncology was founded in 2018.
-
Where is Pyxis Oncology headquartered?
Pyxis Oncology is headquartered in Boston, MA.
-
What is the size of Pyxis Oncology?
Pyxis Oncology has 54 total employees.
-
What industry is Pyxis Oncology in?
Pyxis Oncology’s primary industry is Drug Discovery.
-
Is Pyxis Oncology a private or public company?
Pyxis Oncology is a Public company.
-
What is Pyxis Oncology’s stock symbol?
The ticker symbol for Pyxis Oncology is PYXS.
-
What is the current stock price of Pyxis Oncology?
As of 02-Dec-2024 the stock price of Pyxis Oncology is $2.00.
-
What is the current market cap of Pyxis Oncology?
The current market capitalization of Pyxis Oncology is $119M.
-
What is Pyxis Oncology’s current revenue?
The trailing twelve month revenue for Pyxis Oncology is $16.1M.
-
Who are Pyxis Oncology’s competitors?
NexImmune, Anaveon, Nkarta Therapeutics, Arvinas, and CytomX Therapeutics are some of the 55 competitors of Pyxis Oncology.
-
What is Pyxis Oncology’s annual earnings per share (EPS)?
Pyxis Oncology’s EPS for 12 months was -$1.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
